To overcome the progressive loss of CAR expression, we assessed the feasibility of using cryopreserved NK cells engineered with an anti-CD138 CAR, combined with histone deacetylase inhibitors, thereby improving treatment outcomes for multiple myeloma. Here, SDC1 is linked to plasma cell myeloma.